Literature DB >> 21136203

Intracellular osteopontin (iOPN) and immunity.

Makoto Inoue1, Mari L Shinohara.   

Abstract

Osteopontin (OPN) is a protein involved in various pathophysiological events. OPN has been studied as a secreted protein, but recent reports showed that OPN can be found in the cytoplasm and the nucleus. Therefore, some OPN molecules are not secreted and stay in cells. Such intracellular OPN (iOPN) has biological functions distinct from secreted OPN (sOPN). iOPN is involved in cytoskeletal rearrangement and in signal transduction pathways downstream of innate immune receptors, such as Toll-like receptors (TLRs), as an adaptor or scaffolding protein. Although sOPN and iOPN are generated from the same Opn mRNA species, biological outcomes mediated by two isoforms can be different. It would be necessary to delineate which isoform of OPN is responsible for pathophysiological events.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21136203      PMCID: PMC3509172          DOI: 10.1007/s12026-010-8179-5

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  88 in total

1.  Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon.

Authors:  P Acland; M Dixon; G Peters; C Dickson
Journal:  Nature       Date:  1990-02-15       Impact factor: 49.962

Review 2.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

3.  Osteopontin-c is a selective marker of breast cancer.

Authors:  Mana Mirza; Elizabeth Shaughnessy; John K Hurley; Kristie A Vanpatten; Gary A Pestano; Bin He; Georg F Weber
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

4.  Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness.

Authors:  Lisa de las Fuentes; C Charles Gu; Santhosh J Mathews; Joann L Reagan; Nicholas P Ruthmann; Alan D Waggoner; Chung-Fang Lai; Dwight A Towler; Víctor G Dávila-Román
Journal:  J Am Soc Echocardiogr       Date:  2008-04-11       Impact factor: 5.251

5.  Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

Authors:  Mari L Shinohara; June-Ho Kim; Virgilio A Garcia; Harvey Cantor
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

6.  Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells.

Authors:  Mari L Shinohara; Hye-Jung Kim; June-Ho Kim; Virgilio A Garcia; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-14       Impact factor: 11.205

7.  Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor.

Authors:  B Bugler; F Amalric; H Prats
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

8.  Two isoforms of murine hck, generated by utilization of alternative translational initiation codons, exhibit different patterns of subcellular localization.

Authors:  P Lock; S Ralph; E Stanley; I Boulet; R Ramsay; A R Dunn
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

9.  Osteopontin mediates Stat1 degradation to inhibit iNOS transcription in a cecal ligation and puncture model of sepsis.

Authors:  Hongtao Guo; Philip Y Wai; Zhiyong Mi; Chengjiang Gao; Jinping Zhang; Paul C Kuo
Journal:  Surgery       Date:  2008-05-16       Impact factor: 3.982

10.  cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN).

Authors:  M F Young; J M Kerr; J D Termine; U M Wewer; M G Wang; O W McBride; L W Fisher
Journal:  Genomics       Date:  1990-08       Impact factor: 5.736

View more
  64 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

3.  Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis.

Authors:  Karl Katholnig; Birgit Schütz; Stephanie D Fritsch; David Schörghofer; Monika Linke; Nyamdelger Sukhbaatar; Julia M Matschinger; Daniela Unterleuthner; Martin Hirtl; Michaela Lang; Merima Herac; Andreas Spittler; Andreas Bergthaler; Gernot Schabbauer; Michael Bergmann; Helmut Dolznig; Markus Hengstschläger; Mark A Magnuson; Mario Mikula; Thomas Weichhart
Journal:  JCI Insight       Date:  2019-10-17

4.  Cutting edge: Role of osteopontin and integrin αv in T cell-mediated anti-inflammatory responses in endotoxemia.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

5.  Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling.

Authors:  Xin Duan; Mu Qiao; Fengfeng Bei; In-Jung Kim; Zhigang He; Joshua R Sanes
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

6.  The role of α9β1 integrin and its ligands in the development of autoimmune diseases.

Authors:  Shigeyuki Kon; Toshimitsu Uede
Journal:  J Cell Commun Signal       Date:  2017-10-03       Impact factor: 5.782

7.  Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure.

Authors:  Longgen Liu; Jianchun Lu; Chunyan Ye; Lin Lin; Shuqin Zheng; Hongyu Zhang; Qing Lan; Yuan Xue
Journal:  Biomed Rep       Date:  2017-12-13

8.  Wogonin suppresses osteopontin expression in adipocytes by activating PPARα.

Authors:  Ye-min Zhang; Ming-xin Li; Zhao Tang; Chang-hua Wang
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

Review 9.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

10.  NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis.

Authors:  Elyse Di Marco; Stephen P Gray; Kit Kennedy; Cedric Szyndralewiez; Alicia N Lyle; Bernard Lassègue; Kathy K Griendling; Mark E Cooper; Harald H H W Schmidt; Karin A M Jandeleit-Dahm
Journal:  Free Radic Biol Med       Date:  2016-07-19       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.